NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio
Announces Recent Patent Issuances and Allowances in Canada and Japan
News provided by
Share this article
LOS ANGELES, March 11, 2021 /PRNewswire/
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to treat neurological and neuropsychiatric disorders, announced today that the following patents have issued or received notices of allowance in Canada and Japan:
Canadian patent no. 2776694 entitled Devices, Systems, and Methods for Treatment of Neuropsychiatric Disorders; issued November 17, 2020
Canadian patent no. 2821981 entitled Devices, Systems and Methods for Treatment of Medical Disorders; issued January 12, 2021
Japanese patent application no. 2019-107209 entitled Devices and Methods for Treatment of Psychiatric Disorders; notice of allowance received